期刊档案 · 医学-免疫学
Cancer Immunology Immunotherapy
ISSN 0340-7004 · eISSN 1432-0851 · Springer Berlin Heidelberg · UNITED STATES · Monthly · 创刊 1976
Cancer Immunology Immunotherapy 中科院 医学 3区(2025 年升级版),影响因子 5.75,完全开放获取,APC 约 4,790 美元,近 24 个月 95 篇文章投稿到接收中位 107 天,录用比例较易(社区反馈),2025 年发文 374 篇,SCIE、Scopus 收录。
研究范围
研究范围与定位
Cancer Immunology Immunotherapy 由 Springer Berlin Heidelberg 出版,属中科院医学大类(2025 升级版3区)。按 OpenAlex 近年发文统计,该刊主要发表 Immunotherapy and Immune Responses、Cancer Immunotherapy and Biomarkers、Immune Cell Function and Interaction 等主题的论文,这 3 个主题约占 48.4%,主导子领域为 Immunology。(根据 OpenAlex 主题统计与中科院分区数据生成)
• 发表癌症免疫学和免疫治疗领域的基础与转化研究 • 自1976年创刊以来,发表肿瘤免疫学领域的重大进展 • 开放获取为您的研究提供更高的曝光度 Springer 覆盖科学、技术、医学及社会科学等广泛学科领域, 既支持基础研究, 也服务于现实应用需求。依托成熟稳健的学术出版传统, Springer 将专业学术社群与可应用的知识成果紧密连接。
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), Sociedad Española de Immunologia-Grupo Español de ImmunoTerapia (SEI-GEIT), and Cancer Immunotherapy & Immunomonitoring (CITIM).
摘自期刊官网 Aims & Scope
研究方向(LetPub):医学-免疫学
主编 Haidong Dong出版商官网
编委会国家分布:中国大陆 8 位(约 21%);主要国家 美国 13、中国 8、德国 4、英国 3、意大利 3(共 39 位编委标注了国家) 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计,占比为近似值
- Immunotherapy and Immune ResponsesImmunology and Microbiology20.1%
- Cancer Immunotherapy and BiomarkersMedicine14.8%
- Immune Cell Function and InteractionImmunology and Microbiology13.6%
- CAR-T cell therapy researchMedicine7.9%
- T-cell and B-cell ImmunologyImmunology and Microbiology6.8%
- Monoclonal and Polyclonal Antibodies ResearchMedicine6.1%
- Immune cells in cancerImmunology and Microbiology4.9%
- Glycosylation and Glycoproteins ResearchBiochemistry, Genetics and Molecular Biology2.4%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表( 2025年3月升级版)医学 3 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 3 区 |
| 小类 | 免疫学IMMUNOLOGY | 3 区 |
| 小类 | 肿瘤学ONCOLOGY | 3 区 |
Top 期刊:否综述期刊:否
《新锐期刊分区表》( 2026年3月发布)医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 肿瘤学ONCOLOGY | 2 区 |
| 小类 | 免疫学IMMUNOLOGY | 2 区 |
Top 期刊:否综述期刊:未标注
期刊分区表( 2023年12月旧的升级版)医学 2 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 2 区 |
| 小类 | 免疫学IMMUNOLOGY | 3 区 |
| 小类 | 肿瘤学ONCOLOGY | 3 区 |
Top 期刊:否综述期刊:否
数据库收录
SCIEScopusDOAJLetPub
国际期刊预警名单:各版本均未列入LetPub
期刊官网自述收录
MEDLINEEmbaseCASCurrent Contents出版商官网
其他:Google Scholar、EBSCO、ProQuest、Dimensions、CNKI、Baidu、AGRICOLA、Naver、OCLC、Portico、CLOCKSS、Semantic Scholar
期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。
不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 5.75LetPub ·
- 影响因子(出版商公布) 2025
- 5.8出版商官网 ·
- 五年影响因子(出版商公布) 2025
- 5.6出版商官网 ·
- CiteScore 2026-06
- 9.5LetPub ·
- SJR 2026-06
- 1.81LetPub ·
- SNIP 2026-06
- 1.03LetPub ·
- h-index
- 104LetPub ·
- h-index
- 166OpenAlex ·
- i10-index
- 4,964OpenAlex ·
- 两年平均被引
- 5.6OpenAlex ·
- 自引率
- 3.4%LetPub ·
- Gold OA 文章占比
- 87.15%LetPub ·
发文规模
- 年文章数
- 359LetPub ·
- 年下载量(出版商公布) 2025
- 2,300,000出版商官网 ·
逐年发文量 OpenAlex 统计 · 累计 7,732 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 306 | 306 | 184 |
| 2025 | 374 | 374 | 1,874 |
| 2024 | 301 | 301 | 3,437 |
| 2023 | 223 | 223 | 3,698 |
| 2022 | 233 | 233 | 5,145 |
| 2021 | 320 | 318 | 9,029 |
不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
107 天投稿到接收中位数 · P25–P75 70 天 – 154 天
- 接收到上线
- 中位数 22 天(95 篇)
- 投稿到上线
- 中位数 137 天
- 样本
- 95 篇有投稿与接收日期的文章(窗口内共 727 篇),最近一篇接收于
只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度(社区反馈)
- 平均1月LetPub ·
- 平均录用比例(社区反馈)
- 较易LetPub ·
- 投稿到首次决定
- 2 天出版商官网 ·
- 投稿到发表(期刊自报)
- 约 14 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
所有文章开放获取,通常向作者收取文章处理费(APC)。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | EUR 3,590 / USD 4,790 / GBP 2,990 | 有 | CC BY、CC BY-NC-ND | |
| OpenAlex | USD 4,590 / EUR 3,490 / GBP 2,890 | — | — | |
| 出版商官网 | 有,金额未公布 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。
投稿要求
文章类型与投稿政策(官网)
征稿中的专刊3 个,按截稿日期
出版商官网投稿准备要点4 项,摘自作者指南
- 摘要
- 150–250 词
- 关键词
- ≥ 4 个
- 参考文献格式
- 顺序编码制(按引用顺序编号)
- 推荐审稿人
- 可选
接收的文章类型15 种,含篇幅限制
- brief research reportsBrief research reports – featuring clear and concise conclusion supported by solid data at small-scale basic research or early stage of clinical studies, 2000 w…未说明篇幅
- clinical trial reportsClinical Trial Reports – please review the guidelines of Original research Articles and include relevant immunological data.未说明篇幅
- commentaryThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
- editorialThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
- editorialsEditorials- it is a forum for exchanging ideas, innovations, new updates in a fast-moving field or topic. Word limitation 1200 with up to 10 references and one …未说明篇幅
- letterThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
- letter to the editorsLetter to the Editors – This journal occasionally accepts letters to the Editors pertaining primarily to articles published in the Journal. Text is limited to 7…未说明篇幅
- meta-analysisThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
- meta-analysis reviewsMeta-analysis Reviews - Must be based on a rigorous methodological/statistical approach described in detail in the methods section applied to a relevant clinica…未说明篇幅
- opinionThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
- original research articleThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
- original research articlesOriginal research articles – featuring three innovations: new concept, new mechanism or new therapy, in basic science and clinical studies, text limit 4000 word…未说明篇幅
- research reportThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
- reviewThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…正文 ≤ 4,000 词
- systematic reviewThe journal Cancer Immunology, Immunotherapy publishes the following types of papers: o Original research articles – featuring three innovations: new concept, n…未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、试验注册 / 报告规范
- AI 使用 Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
原文 ↗出版商官网 ·- 作者资格 Authorship, Criteria and Contributions
All authors must approve all versions of a submitted manuscript. All authors of accepted articles must accept responsibility for the manuscript’s content by signing an authorship form affirming that they have met the following three criteria for authorship: 1. Substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of results. 2. Substantial scie…
原文 ↗出版商官网 ·- 利益冲突 Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
原文 ↗出版商官网 ·- 数据可用性 Data Availability
Optional data availability statement encouraged. 模型摘要
This journal encourages authors to provide an optional statement of data availability in their article. Data Availability Statements should include information on where data supporting the results reported in the article can be found, including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. Data availability statements can also indicate whether …
原文 ↗出版商官网 ·- 出版伦理 Compliance with Ethical Standards
Originality and co-author approval required at submission. 模型摘要
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
原文 ↗出版商官网 ·- 许可与版权 Copyright
Articles in Springer Nature open access journals do not require transfer of copyright as the copyright remains with the author. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
原文 ↗出版商官网 ·- 开放获取 Open access publishing
To find out more about publishing your work Open Access in Cancer Immunology, Immunotherapy, including information on fees, funding and licences, visit our Open access publishing page. Back to top
原文 ↗出版商官网 ·- 同行评审 Single-blind peer review
Single-blind peer review 模型摘要
This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review process for these articles is the same as the peer review process of the journal in general. Additionally, if a guest editor authors an article in their issue/collection, they will not handle the peer review process.
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
原文 ↗出版商官网 ·
摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Springer Berlin Heidelberg
- 出版国家或地区
- UNITED STATES
- 出版语言
- English
- 出版周期
- Monthly
- 创刊年份
- 1976
- ISSN
- 0340-7004
- 电子版 ISSN
- 1432-0851
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗LetPub
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
常见问题
关于 Cancer Immunology Immunotherapy 的常见问题
Cancer Immunology Immunotherapy 是中科院几区期刊?
2025 年升级版分区表中,Cancer Immunology Immunotherapy 为医学 3区,小类 免疫学 / 肿瘤学 3 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。
Cancer Immunology Immunotherapy 的影响因子是多少?
LetPub 汇总的最新公布影响因子为 5.75,CiteScore 为 9.5,h-index 为 166。
Cancer Immunology Immunotherapy 的审稿周期多长?
按 2024年10月至2026年10月(近 24 个月)95 篇已发表文章登记的日期,投稿到接收的中位数为 107 天(四分位 70–154 天);投稿社区反馈的平均审稿速度为约 1 个月,平均录用比例反馈为“较易”。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。
Cancer Immunology Immunotherapy 的投稿格式要求是什么?
据期刊作者指南:摘要:150–250 词;关键词:≥ 4 个;参考文献格式:顺序编码制(按引用顺序编号);推荐审稿人:可选。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。
Cancer Immunology Immunotherapy 的编委会里有中国学者吗?
期刊官网编委会页面上标注了国家的 39 位编委中,中国大陆 8 位(约 21%);人数最多的国家是 美国(13 位)、中国(8 位)、德国(4 位)。统计按编委会页面列出的机构国家计,仅供参考。
Cancer Immunology Immunotherapy 被哪些数据库收录?
据 LetPub 与 DOAJ 记录,Cancer Immunology Immunotherapy 被 SCIE、Scopus、DOAJ 收录。期刊官网自述还被 MEDLINE、Embase、CAS、Current Contents 收录,该清单未与各数据库逐一核对。
Cancer Immunology Immunotherapy 是开放获取期刊吗?版面费多少?
Cancer Immunology Immunotherapy 为完全开放获取。APC 约 4,790 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。